Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
Despite already having three products on the market, unlike many of its Hong Kong-listed peers, the drug maker is struggling to cover its daily operational costs Key Takeaways: Mabwell said…
Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
CSPC Pharma taps R&D superstar in quest for new breakout drugs
Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
Junshi narrows its losses but delivers no cure for share price woes
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
Recent Articles
RELATED ARTICLES
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
- Hong Kong gains clout as preferred IPO watering hole for Chinese companies
-
Haitian looks for new financial flavor in Hong Kong IPO
603288.SHG
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
CATL leads new charge of Mainland-listed companies into Hong Kong
300750.SHE
